You are currently on the new version of our website. Access the old version .

519 Results Found

  • Article
  • Open Access
7 Citations
3,078 Views
14 Pages

6 July 2020

Human Papillomavirus 16-associated cancer, affecting primarily the uterine cervix but, increasingly, other body districts, including the head–neck area, will long be a public health problem, despite there being a vaccine. Since the virus oncoge...

  • Article
  • Open Access
15 Citations
10,383 Views
12 Pages

16 March 2018

Canine leishmaniosis has a wide range of disease severity from mild (stage I), to severe (stages II–III), or very severe disease (stage IV). The objective of the study was to evaluate and compare serum antibody levels, Leishmania infantum specific IF...

  • Review
  • Open Access
25 Citations
20,109 Views
23 Pages

Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?

  • Joanie Del Bano,
  • Patrick Chames,
  • Daniel Baty and
  • Brigitte Kerfelec

26 December 2015

As evidenced by the recent approvals of Removab (EU, Trion Pharma) in 2009 and of Blincyto (US, Amgen) in 2014, the high potential of bispecific antibodies in the field of immuno-oncology is eliciting a renewed interest from pharmaceutical companies....

  • Review
  • Open Access
49 Citations
8,537 Views
24 Pages

5 July 2019

Asthma is a common respiratory disease worldwide. Cytokines play a crucial role in the immune system and the inflammatory response to asthma. Abnormal cytokine expression may lead to the development of asthma, which may contribute to pathologies of t...

  • Review
  • Open Access
18 Citations
11,547 Views
19 Pages

Typically, antibody–drug conjugates (ADCs) are made up of a humanized antibody and a small-molecule medication connected by a chemical linker. ADCs’ ability to deliver cytotoxic agents to the specific site with reduced side effects showed...

  • Article
  • Open Access
9 Citations
4,114 Views
11 Pages

Serum Analysis of Women with Early-Stage Breast Cancer Using a Mini-Array of Tumor-Associated Antigens

  • Alma Rosa Oaxaca-Camacho,
  • Oscar René Ochoa-Mojica,
  • Adriana Aguilar-Lemarroy,
  • Luis F. Jave-Suárez,
  • José Francisco Muñoz-Valle,
  • Eduardo Padilla-Camberos,
  • Juan Antonio Núñez-Hernández,
  • Sara E. Herrera-Rodríguez,
  • Moisés Martínez-Velázquez and
  • Rodolfo Hernández-Gutiérrez
  • + 3 authors

21 October 2020

Background: Several studies have shown that patients with cancer have antibodies in serum that react with cellular autoantigens, known as Tumor-Associated Antigens (TAA). The present work aimed to determine whether a mini-array comprising four recomb...

  • Review
  • Open Access
4 Citations
5,104 Views
14 Pages

Clinical Significance and Remaining Issues of Anti-HBc Antibody and HBV Core-Related Antigen

  • Yoshihiko Yano,
  • Itsuko Sato,
  • Takamitsu Imanishi,
  • Ryutaro Yoshida,
  • Takanori Matsuura,
  • Yoshihide Ueda and
  • Yuzo Kodama

Currently, hepatitis B virus (HBV) core antibody (anti-HBc antibody) and HBV core-related antigen (HBcrAg) are widely used as serum markers for diagnosis based on the HBV core region. This review focused on anti-HBc antibodies and HBcrAg and aimed to...

  • Review
  • Open Access
9 Citations
6,458 Views
24 Pages

The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond

  • Irene Strassl,
  • Martin Schreder,
  • Normann Steiner,
  • Jakob Rudzki,
  • Hermine Agis,
  • Tina Künz,
  • Nino Müser,
  • Wolfgang Willenbacher,
  • Andreas Petzer and
  • Maria Theresa Krauth
  • + 1 author

19 September 2021

Since the introduction of first-generation proteasome inhibitors and immunomodulatory agents, the multiple myeloma (MM) treatment landscape has undergone a remarkable development. Most recently, immunotherapeutic strategies targeting the B cell matur...

  • Review
  • Open Access
64 Citations
10,156 Views
16 Pages

Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development

  • Anand Rotte,
  • Srikumar Sahasranaman and
  • Nageshwar Budha

21 September 2021

Immune checkpoint blockers have dramatically improved the chances of survival in patients with metastatic cancer, but only a subset of the patients respond to treatment. Search for novel targets that can improve the responder rates and overcome the l...

  • Review
  • Open Access
246 Citations
24,807 Views
22 Pages

Linkers Having a Crucial Role in Antibody–Drug Conjugates

  • Jun Lu,
  • Feng Jiang,
  • Aiping Lu and
  • Ge Zhang

Antibody–drug conjugates (ADCs) comprised of a desirable monoclonal antibody, an active cytotoxic drug and an appropriate linker are considered to be an innovative therapeutic approach for targeted treatment of various types of tumors and cancers, en...

  • Review
  • Open Access
19 Citations
5,179 Views
25 Pages

Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives

  • Cristina Martín-Sabroso,
  • Irene Lozza,
  • Ana Isabel Torres-Suárez and
  • Ana Isabel Fraguas-Sánchez

In the last decade, antibody-drug conjugates (ADCs), normally formed by a humanized antibody and a small drug via a chemical cleavable or non-cleavable linker, have emerged as a potential treatment strategy in cancer disease. They allow to get a sele...

  • Article
  • Open Access
5 Citations
4,338 Views
18 Pages

Functional Changes of Therapeutic Antibodies upon Exposure to Pro-Oxidative Agents

  • Maxime Lecerf,
  • Robin Lacombe,
  • Alexia Kanyavuz and
  • Jordan D. Dimitrov

2 February 2022

Therapeutic monoclonal antibodies have exerted a transformative impact on clinical practice in last two decades. However, development of a therapeutic antibody remains a complex process. Various physiochemical and functional liabilities can compromis...

  • Review
  • Open Access
303 Citations
39,530 Views
31 Pages

Antibody–Drug Conjugates: The Last Decade

  • Nicolas Joubert,
  • Alain Beck,
  • Charles Dumontet and
  • Caroline Denevault-Sabourin

14 September 2020

An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously constructed spacer arm. ADCs have made considerable progress in 1...

  • Article
  • Open Access
3 Citations
3,295 Views
12 Pages

Ultra-Fast and Sensitive Screening for Antibodies against the SARS-CoV-2 S1 Spike Antigen with a Portable Bioelectric Biosensor

  • Sofia Mavrikou,
  • George Marios Papaioannou,
  • Vasileios Tsekouras,
  • Kyriaki Hatziagapiou,
  • Elizabeth Barbara Tatsi,
  • Filippos Filippatos,
  • Christina Kanaka-Gantenbein,
  • Athanasios Michos and
  • Spyridon Kintzios

As a consequence of the progress of the global vaccination against the COVID-19 disease, fast, accurate and affordable assays are needed for monitoring the efficiency of developing immunity against the coronavirus at the population level. In this con...

  • Review
  • Open Access
24 Citations
6,701 Views
15 Pages

Prophylactic Hepatitis E Vaccines: Antigenic Analysis and Serological Evaluation

  • Yike Li,
  • Xiaofen Huang,
  • Zhigang Zhang,
  • Shaowei Li,
  • Jun Zhang,
  • Ningshao Xia and
  • Qinjian Zhao

16 January 2020

Hepatitis E virus (HEV) infection causes sporadic outbreaks of acute hepatitis worldwide. HEV was previously considered to be restricted to resource-limited countries with poor sanitary conditions, but increasing evidence implies that HEV is also a p...

  • Article
  • Open Access
1,327 Views
13 Pages

Single Center Characterization of a Cohort of Salivary Gland Carcinomas

  • Ria Winkelmann,
  • Maja Weißgerber,
  • Peter J. Wild,
  • Julia Bein,
  • Maximilian Fleischmann,
  • Melanie Demes,
  • Panagiotis Balermpas,
  • Andreas Loth,
  • Katrin Bankov and
  • Jens von der Grün

29 August 2024

Salivary gland cancer (SGC) is a rare cancer that can present a diagnostic challenge to pathologists, with emerging, but still limited options for the treatment of recurrent/metastatic disease. We aimed to characterize the cohort of salivary gland ca...

  • Review
  • Open Access
3 Citations
5,106 Views
15 Pages

Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates

  • Christie P. M. Verkleij,
  • Wassilis S. C. Bruins,
  • Sonja Zweegman and
  • Niels W. C. J. van de Donk

1 March 2021

In the 2010s, immunotherapy revolutionized the treatment landscape of multiple myeloma. CD38-targeting antibodies were initially applied as monotherapy in end-stage patients, but are now also approved by EMA/FDA in combination with standards-of-care...

  • Article
  • Open Access
1,492 Views
21 Pages

Influence of High Eimeria tenella Immunization Dosages on Total Oocyst Output and Specific Antibodies Recognition Response in Hybrid Pullets (Gallus gallus)—A Pilot Study

  • Marco A. Juarez-Estrada,
  • Guillermo Tellez-Isaias,
  • Víctor M. Petrone-Garcia,
  • Amanda Gayosso-Vazquez,
  • Xochitl Hernandez-Velasco and
  • Rogelio A. Alonso-Morales

26 January 2025

Background: Two high primary-immunization doses of a wild-type E. tenella strain were assessed in healthy pullets (5K versus 10K sporulated oocysts/bird) to understand the effects of coccidia infection. Methods: Acquired immunity was evaluated follow...

  • Article
  • Open Access
7 Citations
2,391 Views
11 Pages

Frequency of Autoantibodies on Non-Hodgkin Lymphoma

  • Sonia Guadalupe Barreno-Rocha,
  • Sandra Guzmán-Silahua,
  • Ernesto Germán Cardona-Muñoz,
  • Maria Guadalupe Zavala-Cerna,
  • David Eduardo Muñoz Gaytan,
  • Carlos Riebeling-Navarro,
  • Benjamín Rubio-Jurado and
  • Arnulfo Hernán Nava-Zavala

6 August 2023

(1) Background: Non-Hodgkin Lymphoma is a neoplasm that can significantly compromise the immune system, but timely assessment can change the patient outcome. In cancer, the activation of the immune system could lead to the secretion of autoantibodies...

  • Article
  • Open Access
13 Citations
4,544 Views
15 Pages

Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial

  • Aleksandr V. Kudriavtsev,
  • Anna V. Vakhrusheva,
  • Nickolay A. Kryuchkov,
  • Maria E. Frolova,
  • Konstantin A. Blagodatskikh,
  • Taras V. Ivanishin,
  • Milana Djonovic,
  • Ekaterina A. Romanovskaya-Romanko,
  • Anton N. Kovalenko and
  • Igor V. Krasilnikov
  • + 6 authors

1 February 2023

COVID-19, being a life-threatening infection that evolves rapidly, remains a major public health concern calling for the development of vaccines with broad protection against different pathogenic strains and high immunogenicity. Aside from this, othe...

  • Review
  • Open Access
41 Citations
8,276 Views
17 Pages

24 December 2019

Detection of biomarkers has raised much interest recently due to the need for disease diagnosis and personalized medicine in future point-of-care systems. Among various biomarkers, antibodies are an important type of detection target due to their pot...

  • Article
  • Open Access
1 Citations
1,357 Views
12 Pages

Fatty Acid Binding Protein 4 Could Be a Linking Biomarker Between Periodontitis and Systemic Diseases

  • Jiwon Song,
  • Soo-Min Ok,
  • Eun-Young Kwon,
  • Hyun-Joo Kim,
  • Ju-Youn Lee and
  • Ji-Young Joo

Background/Objectives: This study aims to investigate the relationship between serum fatty acid-binding protein 4 (FABP4) levels and the severity of periodontitis in systemically healthy individuals. Additionally, the study examines whether non-surgi...

  • Review
  • Open Access
57 Citations
8,861 Views
19 Pages

Molecular Selection, Modification and Development of Therapeutic Oligonucleotide Aptamers

  • Yuanyuan Yu,
  • Chao Liang,
  • Quanxia Lv,
  • Defang Li,
  • Xuegong Xu,
  • Baoqin Liu,
  • Aiping Lu and
  • Ge Zhang

Monoclonal antibodies are the dominant agents used in inhibition of biological target molecules for disease therapeutics, but there are concerns of immunogenicity, production, cost and stability. Oligonucleotide aptamers have comparable affinity and...

  • Article
  • Open Access
13 Citations
3,528 Views
18 Pages

Effective Functional Immunogenicity of a DNA Vaccine Combination Delivered via In Vivo Electroporation Targeting Malaria Infection and Transmission

  • Yi Cao,
  • Clifford T. H. Hayashi,
  • Fidel Zavala,
  • Abhai K. Tripathi,
  • Hayk Simonyan,
  • Colin N. Young,
  • Leor C. Clark,
  • Yukari Usuda,
  • Jacob M. Van Parys and
  • Nirbhay Kumar

16 July 2022

Plasmodium falciparum circumsporozoite protein (PfCSP) and Pfs25 are leading candidates for the development of pre-erythrocytic and transmission-blocking vaccines (TBV), respectively. Although considerable progress has been made in developing Pf...

  • Review
  • Open Access
46 Citations
10,895 Views
29 Pages

BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma

  • Shih-Feng Cho,
  • Liang Lin,
  • Lijie Xing,
  • Yuyin Li,
  • Tengteng Yu,
  • Kenneth C Anderson and
  • Yu-Tzu Tai

5 June 2020

The treatment of multiple myeloma (MM) has entered into a new era of immunotherapy. Novel immunotherapies will significantly improve patient outcome via simultaneously targeting malignant plasma cell (PC) and reversing immunocompromised bone marrow (...

  • Article
  • Open Access
6 Citations
7,123 Views
14 Pages

Structural Basis of a Novel Agonistic Anti-OX40 Antibody

  • Jing Zhang,
  • Xiaoyong Jiang,
  • Han Gao,
  • Fei Zhang,
  • Xin Zhang,
  • Aiwu Zhou,
  • Ting Xu and
  • Haiyan Cai

31 August 2022

Agonistic antibodies targeting co-stimulating receptor OX40 on T cells are considered as important as (or complementary to) the immune checkpoint blockers in cancer treatment. However, none of these agonistic antibodies have reached the late stage of...

  • Case Report
  • Open Access
8 Citations
4,619 Views
9 Pages

Decompensated Cirrhosis as Presentation of LKM1/LC1 Positive Type 2 Autoimmune Hepatitis in Adulthood. A Rare Clinical Entity of Difficult Management

  • Alessandro Granito,
  • Simona Pascolini,
  • Chiara Ricci,
  • Marco Ferronato,
  • Luigi Muratori,
  • Francesco Vasuri,
  • Tania Franceschini,
  • Marco Lenzi and
  • Paolo Muratori

Background: Autoimmune hepatitis (AIH) is a chronic and aggressive liver disease that rapidly evolves into cirrhosis and end-stage liver disease if not timely diagnosed and treated with immunosuppressive therapy. AIH is classified into type 1 and typ...

  • Article
  • Open Access
16 Citations
7,676 Views
15 Pages

A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity

  • Yan Feng,
  • Kun Xie,
  • Yanxin Yin,
  • Bingyu Li,
  • Chenyu Pi,
  • Xiaoqing Xu,
  • Tao Huang,
  • Jingming Zhang,
  • Bo Wang and
  • Jianmin Fang
  • + 1 author

21 January 2022

B7-H3 plays an important role in tumor apoptosis, proliferation, adhesion, angiogenesis, invasion, migration, and evasion of immune surveillance. It is overexpressed in various human solid tumor tissues. In patients, B7-H3 overexpression correlates w...

  • Review
  • Open Access
7 Citations
7,856 Views
23 Pages

Immune mechanisms play an important role in the pathogenesis of glomerulonephritis (GN), with autoimmunity being the main underlying pathogenetic process of both primary and secondary GN. We present three autoimmune diseases mediated by different aut...

  • Review
  • Open Access
11 Citations
5,447 Views
13 Pages

27 March 2024

Diffuse large B-cell lymphoma (DLBCL) is the most prevalent subtype of lymphoma, comprising heterogeneous patient subgroups with distinctive biological and clinical characteristics. The R-CHOP combination (rituximab, cyclophosphamide, doxorubicin, vi...

  • Review
  • Open Access
43 Citations
9,272 Views
35 Pages

Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers

  • Lindsey Carlsen,
  • Kelsey E. Huntington and
  • Wafik S. El-Deiry

17 February 2022

Though early-stage colorectal cancer has a high 5 year survival rate of 65–92% depending on the specific stage, this probability drops to 13% after the cancer metastasizes. Frontline treatments for colorectal cancer such as chemotherapy and rad...

  • Article
  • Open Access
2 Citations
2,104 Views
16 Pages

Serum Anti-Zta and Anti-LMP1 Antibodies in Oropharyngeal Cancer Related to Epstein–Barr Virus—Diagnostic Usefulness

  • Anna Polz,
  • Kamal Morshed,
  • Bartłomiej Drop,
  • Andrzej Drop and
  • Małgorzata Polz-Dacewicz

13 January 2024

Background: The role of the Epstein–Barr virus (EBV), the first known human oncogenic virus, in the development of nasopharyngeal cancer (NPC) is already well documented. There are few studies in the available scientific literature on oropharyn...

  • Article
  • Open Access
23 Citations
4,841 Views
10 Pages

2 September 2021

Leishmaniosis is an important zoonotic protozoan disease primarily spread to the Mediterranean region by Leishmania infantum, the predominant protozoan species, which accounts for the majority of cases. Development of disease depends on the immune re...

  • Brief Report
  • Open Access
2 Citations
2,460 Views
14 Pages

Impact of Light-Chain Variants on the Expression of Therapeutic Monoclonal Antibodies in HEK293 and CHO Cells

  • Alexander Veber,
  • Dennis Lenau,
  • Polyniki Gkragkopoulou,
  • David Kornblüh Bauer,
  • Ingo Focken,
  • Wulf Dirk Leuschner,
  • Christian Beil,
  • Sandra Weil,
  • Ercole Rao and
  • Thomas Langer

Recombinantly produced monoclonal antibodies (mabs) belong to the fastest growing class of biotherapeutics. In humans, antibodies are classified into five different classes: IgA, IgD, IgE, IgG and IgM. Most of the therapeutic mabs used in the clinic...

  • Article
  • Open Access
4 Citations
3,912 Views
12 Pages

Twist1 Inactivation in Dmp1-Expressing Cells Increases Bone Mass but Does Not Affect the Anabolic Response to Sclerostin Neutralization

  • Karl J. Lewis,
  • Roy B-J Choi,
  • Emily Z. Pemberton,
  • Whitney A. Bullock,
  • Anthony B. Firulli and
  • Alexander G. Robling

9 September 2019

Wnt signaling plays a major role in bone metabolism. Advances in our understanding of secreted regulators of Wnt have yielded several therapeutic targets to stimulate osteoanabolism—the most promising of which is the Wnt inhibitor sclerostin. S...

  • Review
  • Open Access
19 Citations
5,518 Views
27 Pages

Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma

  • James Ackley,
  • Miguel Armenta Ochoa,
  • Delta Ghoshal,
  • Krishnendu Roy,
  • Sagar Lonial and
  • Lawrence H. Boise

24 September 2021

Multiple myeloma is an incurable disease of malignant plasma cells and an ideal target for modern immune therapy. The unique plasma cell biology maintained in multiple myeloma, coupled with its hematological nature and unique bone marrow microenviron...

  • Review
  • Open Access
83 Citations
14,819 Views
10 Pages

Targeted Therapies for Brain Metastases from Breast Cancer

  • Vyshak Alva Venur and
  • José Pablo Leone

13 September 2016

The discovery of various driver pathways and targeted small molecule agents/antibodies have revolutionized the management of metastatic breast cancer. Currently, the major targets of clinical utility in breast cancer include the human epidermal growt...

  • Review
  • Open Access
52 Citations
7,469 Views
34 Pages

Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines

  • Carlotta Biagi,
  • Arianna Dondi,
  • Sara Scarpini,
  • Alessandro Rocca,
  • Silvia Vandini,
  • Giulia Poletti and
  • Marcello Lanari

11 November 2020

Respiratory syncytial virus (RSV) is the main cause of acute respiratory tract infections in infants and it also induces significant disease in the elderly. The clinical course may be severe, especially in high-risk populations (infants and elderly),...

  • Review
  • Open Access
19 Citations
5,029 Views
27 Pages

25 September 2022

Infectious diseases, caused by various pathogens in the clinic, threaten the safety of human life, are harmful to physical and mental health, and also increase economic burdens on society. Infections are a complex mechanism of interaction between pat...

  • Review
  • Open Access
21 Citations
5,323 Views
17 Pages

Antibody Conjugates for Sarcoma Therapy: How Far along Are We?

  • Letizia Polito,
  • Giulia Calafato,
  • Massimo Bortolotti,
  • Cecilia Chiarelli Olivari,
  • Stefania Maiello and
  • Andrea Bolognesi

Sarcomas are one of the most difficult type of cancer to manage and treat because of their extremely heterogeneous molecular and morphological features. Despite the progress made over the years in the establishment of standard protocols for high and...

  • Review
  • Open Access
43 Citations
11,109 Views
19 Pages

4 March 2020

As a non-antibody scaffold, monobodies based on the fibronectin type III (FN3) domain overcome antibody size and complexity while maintaining analogous binding loops. However, antibodies and their derivatives remain the gold standard for the design o...

  • Review
  • Open Access
72 Citations
38,908 Views
27 Pages

Ten Approaches That Improve Immunostaining: A Review of the Latest Advances for the Optimization of Immunofluorescence

  • Ricardo Piña,
  • Alma I. Santos-Díaz,
  • Erika Orta-Salazar,
  • Azucena Ruth Aguilar-Vazquez,
  • Carola A. Mantellero,
  • Isabel Acosta-Galeana,
  • Argel Estrada-Mondragon,
  • Mara Prior-Gonzalez,
  • Jadir Isai Martinez-Cruz and
  • Abraham Rosas-Arellano

26 January 2022

Immunostaining has emerged as one of the most common and valuable techniques that allow the localization of proteins at a quantitative level within cells and tissues using antibodies coupled to enzymes, fluorochromes, or colloidal nanogold particles....

  • Article
  • Open Access
676 Views
25 Pages

Vaccination with a Trypanosoma cruzi Protein Extract Plus BCG∆BCG1419c Promotes a Balanced Th1/Th2 Immune Profile That Improves Control of Acute Chagas Disease in BALB/c Mice

  • Olivia Rodríguez-Morales,
  • Minerva Arce-Fonseca,
  • Dulce Mata-Espinosa,
  • Alberto Aranda-Fraustro,
  • José Luis Rosales-Encina and
  • Mario Alberto Flores-Valdez

Adjuvants in vaccine candidates against Chagas disease (ChD) have been tested with the aim of improving efficacy against this disease. Trypanosoma cruzi total protein extract (TcTPE) combined with Mycobacterium bovis BCG Pasteur strain ATCC 35734 or...

  • Article
  • Open Access
8 Citations
2,796 Views
10 Pages

Redox Status in Canine Leishmaniasis

  • Fausto Quintavalla,
  • Giuseppina Basini,
  • Simona Bussolati,
  • Gennaro Giuseppe Carrozzo,
  • Antonio Inglese and
  • Roberto Ramoni

8 January 2021

The World Health Organization defined leishmaniasis as one of the priority attention diseases. Aiming to clarify some aspects of its pathogenetic mechanisms, our study focused on the assessment of redox status in dogs, the main reservoir for Leishman...

  • Review
  • Open Access
97 Citations
13,524 Views
21 Pages

11 January 2019

Molecular imaging is paving the way towards noninvasive detection, staging, and treatment follow-up of diseases such as cancer and inflammation-related conditions. Monoclonal antibodies have long been one of the staples of molecular imaging tracer de...

  • Review
  • Open Access
16 Citations
6,300 Views
24 Pages

In recent years, immune checkpoint inhibitors (ICIs) have revolutionized the treatment of patients with hepatocellular carcinoma (HCC). Following the positive results of the IMbrave150 trial, the combination of atezolizumab (an anti-PD-L1 antibody) a...

  • Article
  • Open Access
2 Citations
1,781 Views
12 Pages

Background: The present study aimed to evaluate and compare the efficacy and safety of anti-programmed cell death protein 1 (anti-PD-1) antibody plus lenvatinib (tyrosine kinase inhibitor) therapy and chemotherapy as the first-line treatment to unres...

  • Review
  • Open Access
14 Citations
5,577 Views
17 Pages

Aptamers in Non-Small Cell Lung Cancer Treatment

  • Irena Wieleba,
  • Kamila Wojas-Krawczyk and
  • Paweł Krawczyk

Aptamers are short, single-stranded oligonucleotides which are capable of specifically binding to single molecules and cellular structures. Aptamers are also known as “chemical antibodies”. Compared to monoclonal antibodies, they are char...

  • Review
  • Open Access
6 Citations
9,685 Views
33 Pages

The Evolving Paradigm of Antibody–Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases

  • Peyton High,
  • Cara Guernsey,
  • Shraddha Subramanian,
  • Joan Jacob and
  • Kendra S. Carmon

Current therapies targeting the human epidermal growth factor receptor (HER) family, including monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs), are limited by drug resistance and systemic toxicities. Antibody–drug conjugates...

  • Review
  • Open Access
8 Citations
3,300 Views
16 Pages

Trends in Melanoma Phase 3 Clinical Trials since 2010: Is there Hope for Advanced Melanoma Therapies beyond Approved Treatment Mechanisms?

  • Hanna H. Kakish,
  • Fasih Ali Ahmed,
  • Mohamedraed Elshami,
  • Alexander W. Loftus,
  • Richard S. Hoehn,
  • John B. Ammori,
  • Lee M. Ocuin,
  • Jordan M. Winter,
  • Jeremy S. Bordeaux and
  • Luke D. Rothermel
  • + 1 author

22 October 2022

Background: Several drugs and treatment modalities are under investigation to improve current melanoma therapy options. This review profiles the trends in clinical trial investment in late-stage melanoma, and anticipates what changes are expected in...

of 11